Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON45870
NL-OMON45870
Completed
Not Applicable

A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of rifampicin on the pharmacokinetics of clazosentan in healthy male subjects. - CS0296 (ID-054-106)

Idorsia Pharmaceuticals Ltd0 sites14 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Idorsia Pharmaceuticals Ltd
Enrollment
14
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Healthy male subjects aged between 18 and 65 years (inclusive) with a Body mass index (BMI) of 18\.0 to 30\.0 kg/m2 (inclusive) at Screening. ;Further inclusion criteria can be found in the protocol section 3\.2\.2\.

Exclusion Criteria

  • •1\. Previous exposure to clazosentan.
  • •2\. Previous exposure to rifampicin within 3 months prior to Screening.
  • •3\. Known hypersensitivity to clazosentan or rifampicin or treatments of the same class, or any of their excipients. ;Further exclusion criteria can be found in the protocol section 3\.2\.3\.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects.
NL-OMON46064Idorsia Pharmaceuticals Ltd14
Completed
Not Applicable
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.
NL-OMON48154Idorsia Pharaceuticals Ltd.56
Completed
Not Applicable
BA/BE trials between two recombinant human bi-phasic insuli
CTRI/2015/05/005827Wockhardt Limited56
Not yet recruiting
Phase 1
A Phase I clinical trial to study the effect of two drugs, Insulin Glargine manufactured by BioGenomics limited and Lantus® by comparing pharmacokinetic and pharmacodynamic properties, safety and tolerability in healthy male volunteers.
CTRI/2022/09/045313BioGenomics Ltd
Recruiting
Phase 1
Phase-I clinical trial of Stelis Insulin Glargine injection 100IU/mL in healthy adults
CTRI/2020/12/030079Stelis Biopharma Pvt Ltd